Study guide
3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
Key Takeaways Explain This Topic AI
Cumulative Dose-Volume Histograms (DVH) plot structure volume percentage against absorbed dose, serving as the primary quantitative plan evaluation tool.
Serial organs (spinal cord, optic chiasm) fail if a small point volume exceeds maximum tolerance (Dmax), whereas parallel organs (lung, liver) depend on mean dose and volume thresholds (Vx).
QUANTEC guidelines constrain full spinal cord dose to Dmax < 45-50 Gy to keep the risk of radiation myelopathy under 1%.
QUANTEC lung tolerance mandates keeping V20 < 30-35% and Mean Lung Dose < 20 Gy to limit symptomatic radiation pneumonitis risk to under 20%.
Mean dose to at least one parotid gland must be kept below 20 Gy (or combined mean < 25 Gy) to prevent severe permanent xerostomia.
Last updated: July 2026
Cumulative vs. Differential Dose-Volume Histograms
A Dose-Volume Histogram (DVH) summarizes 3D dose distribution data from a treatment planning system (TPS) into a 2D graph, plotting radiation dose on the horizontal axis ( X X X -axis in Gy or %) against tissue volume on the vertical axis ( Y Y Y -axis in % or cm 3 \text{cm}^3 cm 3 ). Volume (%)
- 100% |===== (PTV Target Line) =====+
- | | \
- 80% | | \
- | [ Parallel Organ: Lung ] | \
- 60% |----\ | \
- | \ | \
- 40% | \ | + (D95 Target Coverage)
- | [ Serial Organ: Cord ] | |
- 20% |-------\ | |
- +-------+-------------------+------+--------> Dose (Gy)
- 0 20 Gy 45 Gy 70 Gy
- 1. Cumulative (Integrating) Dose-Volume Histogram
The cumulative DVH is the standard clinical format. Each point ( D , V ) (D, V) ( D , V ) on a cumulative curve represents the total volume of a structure receiving a dose equal to or greater than the corresponding dose value on the X X X -axis.
PTV Target Curve: Ideal shape is a steep box-step curve where 100% of the target volume receives ≥ 95 % \ge 95\% ≥ 95% of the prescription dose, then drops abruptly to 0% beyond 105% of the prescription dose.
Organs at Risk (OAR) Curve: Ideal shape drops rapidly near 0 Gy, staying far to the left of target curves to demonstrate normal tissue sparing.
2. Differential Dose-Volume Histogram
Plots the volume of tissue receiving a dose within specific incremental dose bins (e.g., 1 Gy dose intervals). Differential DVHs are particularly useful for identifying bimodal dose distributions, detecting isolated localized hot spots, and analyzing dose gradients across target boundaries.
Essential Clinical DVH Parameters
Dosimetrists and radiation oncologists utilize specific numerical parameters extracted from cumulative DVHs to verify target coverage and restrict normal tissue toxicity:
V D V_D V D (Volume Constraint Metric): The percentage (or absolute volume in cm 3 \text{cm}^3 cm 3 ) of an organ receiving a dose ≥ D \ge D ≥ D Gy.
V 20 V_{20} V 20 for Lungs: Combined lung volume receiving ≥ 20 Gy \ge 20\text{ Gy} ≥ 20 Gy (predicts radiation pneumonitis risk).
V 50 V_{50} V 50 for Rectum: Rectal volume receiving ≥ 50 Gy \ge 50\text{ Gy} ≥ 50 Gy (predicts Grade ≥ 2 \ge 2 ≥ 2 late rectal bleeding).
V 25 V_{25} V 25 for Heart: Heart volume receiving ≥ 25 Gy \ge 25\text{ Gy} ≥ 25 Gy (predicts long-term cardiac mortality).
D max D_{\max} D m a x (Maximum Point Dose / D 0.03 cc D_{0.03\text{ cc}} D 0.03 cc ): Peak dose delivered to a tiny volume element ( 0.03 cc 0.03\text{ cc} 0.03 cc ). Critical safety evaluation metric for serial organs where localized point damage causes complete organ failure.
D mean D_{\text{mean}} D mean (Mean Organ Dose): Volume-weighted average dose across an entire organ volume. Primary predictive metric for parallel organ toxicity.
D 95 D_{95} D 95 (Prescription Coverage Parameter): Minimum dose received by at least 95% of the PTV target volume. Standard metric for verifying target coverage.
Radiobiological Organ Architecture: Serial vs. Parallel Organs
Understanding normal tissue tolerance requires categorizing organs by Functional Subunit (FSU) architecture. A Functional Subunit is the basic structural and functional cellular group capable of performing organ work.
1. Serial Organs
Organized like links in a chain. Disruption of a single functional subunit at any location along the organ causes complete functional failure of the entire organ or catastrophic clinical damage.
Critical Evaluation Metric: Maximum Point Dose ( D max D_{\max} D m a x or D 0.03 cc D_{0.03\text{ cc}} D 0.03 cc ) . Threshold dose limits must never be exceeded at any point.
Clinical Examples: Spinal Cord (radiation myelopathy / transverse paralysis), Brainstem (neurological necrosis), Optic Chiasm / Optic Nerves (blindness), Femoral Heads (avascular necrosis and hip fracture).
2. Parallel Organs
Organized as independent parallel units operating side-by-side. The organ maintains overall function as long as a critical reserve volume of functional subunits remains undamaged.
Critical Evaluation Metric: Mean Organ Dose ( D mean D_{\text{mean}} D mean ) and Fractional Volume Constraints ( V D V_D V D ) .
Clinical Examples: Lungs (radiation pneumonitis), Parotid Glands (severe permanent xerostomia / dry mouth), Liver (radiation-induced liver disease RILD), Kidneys (renal failure).
QUANTEC Normal Tissue Tolerances
The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines establish standardized, evidence-based dose-volume constraints for adult 3D-CRT and IMRT treatments delivered at standard fractionation (1.8 – 2.0 Gy per fraction).
Organ at Risk (OAR) Organ Architecture QUANTEC Parameter Constraint Primary Clinical Endpoint / Toxicity
Spinal Cord Serial D max < 45 Gy − 50 Gy D_{\max} < 45\text{ Gy} - 50\text{ Gy} D m a x < 45 Gy − 50 Gy Severe myelopathy / Transverse paralysis (< 1% risk)
Brainstem Serial D max < 54 Gy D_{\max} < 54\text{ Gy} D m a x < 54 Gy Neurological necrosis / Cranial nerve deficit
Optic Chiasm / Nerve Serial D max < 54 Gy D_{\max} < 54\text{ Gy} D m a x < 54 Gy ( 50 − 54 Gy 50-54\text{ Gy} 50 − 54 Gy ) Blindness / Optic neuropathy
Parotid Glands Parallel Mean < 20 Gy < 20\text{ Gy} < 20 Gy (1 gland) or < 25 − 26 Gy < 25 - 26\text{ Gy} < 25 − 26 Gy (both) Severe permanent xerostomia (dry mouth)
Rectum Mixed V 50 < 50 % V_{50} < 50\% V 50 < 50% ; V 60 < 35 % V_{60} < 35\% V 60 < 35% ; V 70 < 20 % V_{70} < 20\% V 70 < 20% Grade ≥ 2 \ge 2 ≥ 2 late rectal bleeding / Proctitis
Heart Mixed/Parallel V 25 < 10 % V_{25} < 10\% V 25 < 10% ; Mean < 26 Gy < 26\text{ Gy} < 26 Gy Pericarditis / Long-term cardiac mortality
Femoral Heads Serial D max < 52 Gy D_{\max} < 52\text{ Gy} D m a x < 52 Gy ( V 50 < 5 % V_{50} < 5\% V 50 < 5% ) Necrosis of the femoral head / Fracture
Lungs (Both - PTV) Parallel V 20 < 30 % − 35 % V_{20} < 30\% - 35\% V 20 < 30% − 35% ; Mean < 20 Gy < 20\text{ Gy} < 20 Gy Symptomatic Radiation Pneumonitis (< 20% risk)
Liver (Whole) Parallel Mean < 30 Gy − 32 Gy < 30\text{ Gy} - 32\text{ Gy} < 30 Gy − 32 Gy Radiation-Induced Liver Disease (RILD)
Bladder Mixed V 65 < 50 % V_{65} < 50\% V 65 < 50% ; V 70 < 35 % V_{70} < 35\% V 70 < 35% ; V 80 < 15 % V_{80} < 15\% V 80 < 15% Grade ≥ 3 \ge 3 ≥ 3 late cystitis / Dysuria
Detailed Organ Toxicity & Constraint Summary
Spinal Cord ( D max < 45 − 50 Gy D_{\max} < 45 - 50\text{ Gy} D m a x < 45 − 50 Gy ): Full cord point maximum dose must remain below 45–50 Gy. Exceeding 50 Gy causes demyelination and transverse myelopathy resulting in permanent paralysis.
Brainstem ( D max < 54 Gy D_{\max} < 54\text{ Gy} D m a x < 54 Gy ): Brainstem maximum dose is capped at 54 Gy for the full organ volume to prevent brainstem necrosis and cranial nerve deficits.
Optic Chiasm & Optic Nerves ( D max < 54 Gy D_{\max} < 54\text{ Gy} D m a x < 54 Gy ): Doses above 54 Gy (or 50 Gy at high fraction sizes) lead to severe optic neuropathy and permanent blindness.
Parotid Glands (Mean < 20 Gy < 20\text{ Gy} < 20 Gy / < 25 − 26 Gy < 25 - 26\text{ Gy} < 25 − 26 Gy ): Restricting mean dose to < 20 Gy <20\text{ Gy} < 20 Gy for one gland or < 25 − 26 Gy <25-26\text{ Gy} < 25 − 26 Gy for both combined preserves baseline salivary flow and prevents permanent xerostomia.
Rectum ( V 50 < 50 % V_{50} < 50\% V 50 < 50% ): Keeping the volume receiving ≥ 50 Gy \ge 50\text{ Gy} ≥ 50 Gy under 50% ( V 50 < 50 % V_{50} < 50\% V 50 < 50% ) restricts Grade ≥ 2 \ge 2 ≥ 2 late rectal bleeding and proctitis.
Heart ( V 25 < 10 % V_{25} < 10\% V 25 < 10% , Mean < 26 Gy < 26\text{ Gy} < 26 Gy ): Limiting heart volume receiving 25 Gy to < 10 % <10\% < 10% spares cardiac muscle, preventing pericarditis, coronary artery disease, and late cardiac mortality.
Femoral Heads ( D max < 52 Gy D_{\max} < 52\text{ Gy} D m a x < 52 Gy ): Keeping point maximum dose below 52 Gy prevents radiation-induced avascular necrosis of the femoral head and hip joint fracture.